

Drug Safety Updates

SFDA Approved Risk Management Measures (RMMs)

The summary view in the table includes reviewed and approved Risk minimization measures by SFDA:

Scientific Name	Brand name	Risk	Educational Materials for Healthcare Professionals	Educational Materials for Patients
TOFACITINIB	<u>(Tofaci)</u>	Risk of venous thromboembolism, including deep vein thrombosis (DVT) and pulmonary embolism (PE), cardiovascular risk, myocardial infarction, herpes zoster, tuberculosis (TB), malignancy, gastrointestinal perforations, and lung disease.	<u>HCP GUIDE</u> <u>CHECKLIST</u>	<u>Card Ar</u> <u>Card En</u>
lutetium (177Lu) vipivotide tetraxetan	<u>(Pluvicto)</u>	Risk of radioactivity and precautions should be taken		<u>Guide Ar</u> <u>Guide ENG</u>
zoledronic acid	<u>(ZODRIC)</u>	Osteonecrosis of the Jaw	<u>HCP Guide</u>	<u>Patient Reminder Card-En</u> <u>Patient Reminder Card-Ar</u>

**Measures: additional minimization activities that should be done by the marketing authorization holder to minimize the risk.*